Over the last decade, controlled release drug delivery systems have gained tremendous popularity as they provide a number of advantages over conventional dosage forms including extended drug delivery. Controlled release drug delivery refers to drug delivery methods that allow drugs to be released from the drug product in a predetermined manner for established period of time. Controlled release drug delivery systems enable biocompatible release of therapeutic agents within the body at a predetermined and controlled rate over an extended period with improved efficacy of drugs.
The Global Controlled Release Drug Delivery Market is estimated to be valued at US$ 106.1 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Controlled Release Drug Delivery are Orbis Biosciences, Inc., Merck and Co., Inc., Alkermes plc, Johnson and Johnson, Coating Place, Inc., Corium International, Inc., Depomed, Inc., Pfizer, Inc, Aradigm Corporation, Capsugel., Abbott Laboratories, Roche Holdings AG, AstraZeneca, Baxter International Inc, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company.
The growing prevalence of chronic diseases worldwide and increasing demand for long-lasting drug therapeutics are some of the key factors driving the growth of the global Controlled Release Drug Delivery Market Growth. Additionally, technological advancements in the polymer science and biotechnology have enabled development of novel controlled release drug delivery systems with improved efficiency.
Moreover, the penetration of internet and rising adoption of digital healthcare is enabling patients to get access to advanced treatment options and controlled release drug formulations, thereby propelling the market growth.
Market Trends
Some of the key trends observed in the global controlled release drug delivery market include development of environment-responsive drug delivery systems and adoption of 3D printing technology for manufacturing controlled release drug formulations. Another major trend gaining traction is the growing focus of players on development of controlled release combination drug formulations to treat complex chronic conditions.
Market Opportunities
The rising geriatric population suffering from multiple chronic conditions represents significant growth opportunity for Controlled Release Drug Delivery Market Analysis players. Furthermore, growing investments by pharmaceutical companies as well as venture capital firms into innovative drug delivery technologies is anticipated to present lucrative business prospects over the forecast period. Penetration into untapped emerging markets of Asia Pacific and Latin America also presents substantial growth prospects for stakeholders.
Impact of COVID-19 on Controlled Release Drug Delivery Market Growth
The COVID-19 pandemic has impacted the growth of the controlled release drug delivery market. During the initial lockdown phases imposed globally, the supply chain of raw materials was disrupted significantly. This led to shortage of materials required for manufacturing long-acting drugs. The restrictions on travel and transportation made it difficult to import essential components and ship the finished products. The demand from hospitals reduced temporarily as non-essential medical services were postponed to focus on COVID treatment. However, as the pandemic intensified the need for treatments managing chronic conditions, the demand started reviving.
The research and development activities also slowed down initially. Many ongoing clinical trials evaluating new drug delivery systems got delayed or postponed. The resources from pharmaceutical companies and research institutes were diverted to find treatment options and vaccines for coronavirus. However, as lockdowns eased, the R&D work regained lost momentum. Investments increased to develop controlled release versions of COVID vaccines and therapies. This is expected to boost market growth post-pandemic.
With a shift towards virtual modes of healthcare, the role of long-acting formulations in ensuring medication adherence increased. Their use was promoted for managing chronic diseases from home without frequent physical visits to hospitals or clinics. Telemedicine and home delivery services emerged as a major driving factor driving the demand. Ensuring steady drug levels in the body became critical. Overall, while the short-term impact was negative, COVID-19 highlighted the indispensable need for controlled release drug delivery technologies in the long run.
In terms of geography, North America holds highest value share for controlled release drug delivery market currently. The region is an early adopter of novel drug delivery technologies. Presence of leading pharmaceutical companies and strong healthcare infrastructure supports clinical research. However, Asia Pacific region is expected to witness fastest growth during the forecast period due to rising healthcare expenditures, increasing investments in pharmaceutical R&D and rapidly growing geriatric population in China and India demanding specialty medications for chronic diseases.
Get more insights on Controlled Release Drug Delivery Market
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
Sign in to leave a comment.